Listed

Intellia Therapeutics, Inc.

NTLANasdaqCIK 1652130HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$7.7m, Q2 FY2026
Operating income−$112.8m, Q2 FY2026
Net income−$106.6m, Q2 FY2026
Intellia Therapeutics, Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$m12.0Revenue, Q3 FY2023, three months to 2023-09-30$12.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2024-11-07, accession 0000950170-24-123276.Report this figure(1.9)Revenue, Q4 FY2023, three months to 2023-12-31−$1.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-076550. Derived: 12-month figure less the 9-month figure.Report this figure28.9Revenue, Q1 FY2024, three months to 2024-03-31$28.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-05-08, accession 0000950170-25-066914.Report this figure7.0Revenue, Q2 FY2024, three months to 2024-06-30$7.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-08-07, accession 0000950170-25-104987.Report this figure9.1Revenue, Q3 FY2024, three months to 2024-09-30$9.1m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figure12.9Revenue, Q4 FY2024, three months to 2024-12-31$12.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-076550. Derived: 12-month figure less the 9-month figure.Report this figure16.6Revenue, Q1 FY2025, three months to 2025-03-31$16.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-11, accession 0001193125-26-215740.Report this figure14.2Revenue, Q2 FY2025, three months to 2025-06-30$14.2m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure13.8Revenue, Q3 FY2025, three months to 2025-09-30$13.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figure23.0Revenue, Q4 FY2025, three months to 2025-12-31$23.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001193125-26-076550. Derived: 12-month figure less the 9-month figure.Report this figure15.0Revenue, Q1 FY2026, three months to 2026-03-31$15.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-11, accession 0001193125-26-215740.Report this figure7.7Revenue, Q2 FY2026, three months to 2026-06-30$7.7m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure
Cost of revenue$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$m114Research and development, Q3 FY2023, three months to 2023-09-30$113.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-07, accession 0000950170-24-123276.Report this figure109Research and development, Q4 FY2023, three months to 2023-12-31$109.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001193125-26-076550. Derived: 12-month figure less the 9-month figure.Report this figure112Research and development, Q1 FY2024, three months to 2024-03-31$111.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-08, accession 0000950170-25-066914.Report this figure114Research and development, Q2 FY2024, three months to 2024-06-30$114.2m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-07, accession 0000950170-25-104987.Report this figure123Research and development, Q3 FY2024, three months to 2024-09-30$123.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figure117Research and development, Q4 FY2024, three months to 2024-12-31$116.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001193125-26-076550. Derived: 12-month figure less the 9-month figure.Report this figure108Research and development, Q1 FY2025, three months to 2025-03-31$108.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-11, accession 0001193125-26-215740.Report this figure97.0Research and development, Q2 FY2025, three months to 2025-06-30$97.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure94.7Research and development, Q3 FY2025, three months to 2025-09-30$94.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figure88.7Research and development, Q4 FY2025, three months to 2025-12-31$88.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-02-26, accession 0001193125-26-076550. Derived: 12-month figure less the 9-month figure.Report this figure80.7Research and development, Q1 FY2026, three months to 2026-03-31$80.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-11, accession 0001193125-26-215740.Report this figure82.6Research and development, Q2 FY2026, three months to 2026-06-30$82.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure
Operating income$m(131)Operating income, Q3 FY2023, three months to 2023-09-30−$131.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-07, accession 0000950170-24-123276.Report this figure(140)Operating income, Q4 FY2023, three months to 2023-12-31−$139.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076550. Derived: 12-month figure less the 9-month figure.Report this figure(114)Operating income, Q1 FY2024, three months to 2024-03-31−$114.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-08, accession 0000950170-25-066914.Report this figure(139)Operating income, Q2 FY2024, three months to 2024-06-30−$139.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-07, accession 0000950170-25-104987.Report this figure(145)Operating income, Q3 FY2024, three months to 2024-09-30−$144.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figure(136)Operating income, Q4 FY2024, three months to 2024-12-31−$136.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076550. Derived: 12-month figure less the 9-month figure.Report this figure(121)Operating income, Q1 FY2025, three months to 2025-03-31−$120.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-11, accession 0001193125-26-215740.Report this figure(110)Operating income, Q2 FY2025, three months to 2025-06-30−$110.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure(111)Operating income, Q3 FY2025, three months to 2025-09-30−$111.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figure(98.7)Operating income, Q4 FY2025, three months to 2025-12-31−$98.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076550. Derived: 12-month figure less the 9-month figure.Report this figure(101)Operating income, Q1 FY2026, three months to 2026-03-31−$100.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-11, accession 0001193125-26-215740.Report this figure(113)Operating income, Q2 FY2026, three months to 2026-06-30−$112.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure
Income tax$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$m(122)Net income, Q3 FY2023, three months to 2023-09-30−$122.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-07, accession 0000950170-24-123276.Report this figure(132)Net income, Q4 FY2023, three months to 2023-12-31−$132.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076550. Derived: 12-month figure less the 9-month figure.Report this figure(107)Net income, Q1 FY2024, three months to 2024-03-31−$107.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figure(147)Net income, Q2 FY2024, three months to 2024-06-30−$147.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figure(136)Net income, Q3 FY2024, three months to 2024-09-30−$135.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figure(129)Net income, Q4 FY2024, three months to 2024-12-31−$128.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076550. Derived: 12-month figure less the 9-month figure.Report this figure(114)Net income, Q1 FY2025, three months to 2025-03-31−$114.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure(101)Net income, Q2 FY2025, three months to 2025-06-30−$101.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure(101)Net income, Q3 FY2025, three months to 2025-09-30−$101.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figure(95.8)Net income, Q4 FY2025, three months to 2025-12-31−$95.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001193125-26-076550. Derived: 12-month figure less the 9-month figure.Report this figure(96.2)Net income, Q1 FY2026, three months to 2026-03-31−$96.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure(107)Net income, Q2 FY2026, three months to 2026-06-30−$106.6m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure
Diluted EPS$ per share(1.38)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$1.38 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-07, accession 0000950170-24-123276.Report this figurenot reported(1.12)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$1.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-08, accession 0000950170-25-066914.Report this figure(1.52)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$1.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-07, accession 0000950170-25-104987.Report this figure(1.34)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$1.34 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figurenot reported(1.10)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$1.10 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-11, accession 0001193125-26-215740.Report this figure(0.98)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$0.98 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure(0.92)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.92 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figurenot reported(0.81)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.81 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-11, accession 0001193125-26-215740.Report this figure(0.80)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.80 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure
Basic EPS$ per share(1.38)Basic EPS, Q3 FY2023, three months to 2023-09-30−$1.38 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-07, accession 0000950170-24-123276.Report this figurenot reported(1.12)Basic EPS, Q1 FY2024, three months to 2024-03-31−$1.12 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-08, accession 0000950170-25-066914.Report this figure(1.52)Basic EPS, Q2 FY2024, three months to 2024-06-30−$1.52 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-07, accession 0000950170-25-104987.Report this figure(1.34)Basic EPS, Q3 FY2024, three months to 2024-09-30−$1.34 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figurenot reported(1.10)Basic EPS, Q1 FY2025, three months to 2025-03-31−$1.10 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-11, accession 0001193125-26-215740.Report this figure(0.98)Basic EPS, Q2 FY2025, three months to 2025-06-30−$0.98 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure(0.92)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.92 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figurenot reported(0.81)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.81 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-11, accession 0001193125-26-215740.Report this figure(0.80)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.80 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure

Balance sheet

Cash and equivalents$106.1m, Q2 FY2026
Shareholders' equity$727.7m, Q2 FY2026
Intellia Therapeutics, Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m168Cash and equivalents, Q3 FY2023, at 2023-09-30$168.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2024-11-07, accession 0000950170-24-123276.Report this figure227Cash and equivalents, FY2023, at 2023-12-31$226.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-26, accession 0001193125-26-076550.Report this figure172Cash and equivalents, Q1 FY2024, at 2024-03-31$172.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-08, accession 0000950170-25-066914.Report this figure131Cash and equivalents, Q2 FY2024, at 2024-06-30$130.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-07, accession 0000950170-25-104987.Report this figure120Cash and equivalents, Q3 FY2024, at 2024-09-30$120.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figure189Cash and equivalents, FY2024, at 2024-12-31$189.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-02-26, accession 0001193125-26-076550.Report this figure127Cash and equivalents, Q1 FY2025, at 2025-03-31$126.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-11, accession 0001193125-26-215740.Report this figure156Cash and equivalents, Q2 FY2025, at 2025-06-30$156.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure193Cash and equivalents, Q3 FY2025, at 2025-09-30$193.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figure155Cash and equivalents, FY2025, at 2025-12-31$155.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure135Cash and equivalents, Q1 FY2026, at 2026-03-31$134.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-11, accession 0001193125-26-215740.Report this figure106Cash and equivalents, Q2 FY2026, at 2026-06-30$106.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure
Current assets$m893Current assets, Q3 FY2023, at 2023-09-30$893.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-09, accession 0000950170-23-062011.Report this figure998Current assets, FY2023, at 2023-12-31$998.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-27, accession 0000950170-25-029007.Report this figure884Current assets, Q1 FY2024, at 2024-03-31$884.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-09, accession 0000950170-24-057046.Report this figure757Current assets, Q2 FY2024, at 2024-06-30$757.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0000950170-24-093907.Report this figure711Current assets, Q3 FY2024, at 2024-09-30$710.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-07, accession 0000950170-24-123276.Report this figure640Current assets, FY2024, at 2024-12-31$639.9m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-02-26, accession 0001193125-26-076550.Report this figure551Current assets, Q1 FY2025, at 2025-03-31$551.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-08, accession 0000950170-25-066914.Report this figure496Current assets, Q2 FY2025, at 2025-06-30$495.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-07, accession 0000950170-25-104987.Report this figure582Current assets, Q3 FY2025, at 2025-09-30$581.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figure528Current assets, FY2025, at 2025-12-31$527.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure466Current assets, Q1 FY2026, at 2026-03-31$466.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-11, accession 0001193125-26-215740.Report this figure528Current assets, Q2 FY2026, at 2026-06-30$527.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure
Total assets$m1,243Total assets, Q3 FY2023, at 2023-09-30$1.24bn. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-09, accession 0000950170-23-062011.Report this figure1,301Total assets, FY2023, at 2023-12-31$1.30bn. XBRL concept us-gaap:Assets. 10-K filed 2025-02-27, accession 0000950170-25-029007.Report this figure1,260Total assets, Q1 FY2024, at 2024-03-31$1.26bn. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-09, accession 0000950170-24-057046.Report this figure1,192Total assets, Q2 FY2024, at 2024-06-30$1.19bn. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0000950170-24-093907.Report this figure1,173Total assets, Q3 FY2024, at 2024-09-30$1.17bn. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-07, accession 0000950170-24-123276.Report this figure1,191Total assets, FY2024, at 2024-12-31$1.19bn. XBRL concept us-gaap:Assets. 10-K filed 2026-02-26, accession 0001193125-26-076550.Report this figure986Total assets, Q1 FY2025, at 2025-03-31$986.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-08, accession 0000950170-25-066914.Report this figure899Total assets, Q2 FY2025, at 2025-06-30$898.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-07, accession 0000950170-25-104987.Report this figure925Total assets, Q3 FY2025, at 2025-09-30$925.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figure842Total assets, FY2025, at 2025-12-31$842.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure759Total assets, Q1 FY2026, at 2026-03-31$758.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-11, accession 0001193125-26-215740.Report this figure857Total assets, Q2 FY2026, at 2026-06-30$857.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure
Current liabilities$m92.0Current liabilities, Q3 FY2023, at 2023-09-30$92.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-09, accession 0000950170-23-062011.Report this figure115Current liabilities, FY2023, at 2023-12-31$115.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-27, accession 0000950170-25-029007.Report this figure97.9Current liabilities, Q1 FY2024, at 2024-03-31$97.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-09, accession 0000950170-24-057046.Report this figure105Current liabilities, Q2 FY2024, at 2024-06-30$105.1m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0000950170-24-093907.Report this figure106Current liabilities, Q3 FY2024, at 2024-09-30$105.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-07, accession 0000950170-24-123276.Report this figure111Current liabilities, FY2024, at 2024-12-31$110.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-02-26, accession 0001193125-26-076550.Report this figure113Current liabilities, Q1 FY2025, at 2025-03-31$112.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-08, accession 0000950170-25-066914.Report this figure95.5Current liabilities, Q2 FY2025, at 2025-06-30$95.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-07, accession 0000950170-25-104987.Report this figure93.7Current liabilities, Q3 FY2025, at 2025-09-30$93.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figure104Current liabilities, FY2025, at 2025-12-31$103.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure76.4Current liabilities, Q1 FY2026, at 2026-03-31$76.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-11, accession 0001193125-26-215740.Report this figure79.4Current liabilities, Q2 FY2026, at 2026-06-30$79.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure
Total liabilities$m206Total liabilities, Q3 FY2023, at 2023-09-30$205.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-09, accession 0000950170-23-062011.Report this figure251Total liabilities, FY2023, at 2023-12-31$250.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-27, accession 0000950170-25-029007.Report this figure223Total liabilities, Q1 FY2024, at 2024-03-31$223.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-09, accession 0000950170-24-057046.Report this figure220Total liabilities, Q2 FY2024, at 2024-06-30$220.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-08, accession 0000950170-24-093907.Report this figure211Total liabilities, Q3 FY2024, at 2024-09-30$210.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-07, accession 0000950170-24-123276.Report this figure319Total liabilities, FY2024, at 2024-12-31$319.1m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-02-26, accession 0001193125-26-076550.Report this figure206Total liabilities, Q1 FY2025, at 2025-03-31$206.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-08, accession 0000950170-25-066914.Report this figure184Total liabilities, Q2 FY2025, at 2025-06-30$183.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-07, accession 0000950170-25-104987.Report this figure177Total liabilities, Q3 FY2025, at 2025-09-30$176.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figure171Total liabilities, FY2025, at 2025-12-31$170.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure138Total liabilities, Q1 FY2026, at 2026-03-31$137.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-11, accession 0001193125-26-215740.Report this figure129Total liabilities, Q2 FY2026, at 2026-06-30$129.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure
Shareholders' equity$m1,037Shareholders' equity, Q3 FY2023, at 2023-09-30$1.04bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-07, accession 0000950170-24-123276.Report this figure1,050Shareholders' equity, FY2023, at 2023-12-31$1.05bn. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-02-26, accession 0001193125-26-076550.Report this figure1,036Shareholders' equity, Q1 FY2024, at 2024-03-31$1.04bn. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figure971Shareholders' equity, Q2 FY2024, at 2024-06-30$971.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figure963Shareholders' equity, Q3 FY2024, at 2024-09-30$962.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figure872Shareholders' equity, FY2024, at 2024-12-31$872.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure780Shareholders' equity, Q1 FY2025, at 2025-03-31$779.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure(715)Shareholders' equity, Q2 FY2025, at 2025-06-30−$715.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure748Shareholders' equity, Q3 FY2025, at 2025-09-30$748.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figure671Shareholders' equity, FY2025, at 2025-12-31$671.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure621Shareholders' equity, Q1 FY2026, at 2026-03-31$620.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure728Shareholders' equity, Q2 FY2026, at 2026-06-30$727.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure

Cash flow

Operating cash flow−$83.1m, Q2 FY2026
Capital expenditure$1.8m, Q2 FY2026
Intellia Therapeutics, Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(101)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$101.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-07, accession 0000950170-24-123276. Derived: 9-month figure less the 6-month figure.Report this figure(93.1)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$93.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-076550. Derived: 12-month figure less the 9-month figure.Report this figure(121)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$120.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-08, accession 0000950170-25-066914.Report this figure(58.2)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$58.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-07, accession 0000950170-25-104987. Derived: 6-month figure less the 3-month figure.Report this figure(84.8)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$84.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-269680. Derived: 9-month figure less the 6-month figure.Report this figure(85.2)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$85.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-076550. Derived: 12-month figure less the 9-month figure.Report this figure(149)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$148.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-11, accession 0001193125-26-215740.Report this figure(99.6)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$99.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-337952. Derived: 6-month figure less the 3-month figure.Report this figure(76.9)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$76.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-269680. Derived: 9-month figure less the 6-month figure.Report this figure(69.3)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$69.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001193125-26-076550. Derived: 12-month figure less the 9-month figure.Report this figure(117)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$117.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-11, accession 0001193125-26-215740.Report this figure(83.1)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$83.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001193125-26-337952. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m4.3Capital expenditure, Q3 FY2023, three months to 2023-09-30$4.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-07, accession 0000950170-24-123276. Derived: 9-month figure less the 6-month figure.Report this figure1.5Capital expenditure, Q4 FY2023, three months to 2023-12-31$1.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-076550. Derived: 12-month figure less the 9-month figure.Report this figure2.5Capital expenditure, Q1 FY2024, three months to 2024-03-31$2.5m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-08, accession 0000950170-25-066914.Report this figure1.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$1.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-07, accession 0000950170-25-104987. Derived: 6-month figure less the 3-month figure.Report this figure1.3Capital expenditure, Q3 FY2024, three months to 2024-09-30$1.3m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001193125-25-269680. Derived: 9-month figure less the 6-month figure.Report this figure1.0Capital expenditure, Q4 FY2024, three months to 2024-12-31$981.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-076550. Derived: 12-month figure less the 9-month figure.Report this figure0.7Capital expenditure, Q1 FY2025, three months to 2025-03-31$735.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-11, accession 0001193125-26-215740.Report this figure0.2Capital expenditure, Q2 FY2025, three months to 2025-06-30$239.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-337952. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2025, three months to 2025-09-30$29.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001193125-25-269680. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2025, three months to 2025-12-31$126.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001193125-26-076550. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2026, three months to 2026-03-31$79.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-11, accession 0001193125-26-215740.Report this figure1.8Capital expenditure, Q2 FY2026, three months to 2026-06-30$1.8m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001193125-26-337952. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)133.48m, Q2 FY2026
Intellia Therapeutics, Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares76.0Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3076,047,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-09, accession 0000950170-23-062011.Report this figure87.8Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3187,772,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-09, accession 0000950170-24-057046.Report this figure88.2Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3088,185,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0000950170-24-093907.Report this figure88.6Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3088,645,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-07, accession 0000950170-24-123276.Report this figure95.5Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3195,502,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-08, accession 0000950170-25-066914.Report this figure97.0Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3096,975,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-07, accession 0000950170-25-104987.Report this figure101Diluted shares (weighted), Q3 FY2024, three months to 2024-09-30101,002,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figure104Diluted shares (weighted), Q1 FY2025, three months to 2025-03-31103,500,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-11, accession 0001193125-26-215740.Report this figure104Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30103,732,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure110Diluted shares (weighted), Q3 FY2025, three months to 2025-09-30110,188,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001193125-25-269680.Report this figure118Diluted shares (weighted), Q1 FY2026, three months to 2026-03-31118,490,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-11, accession 0001193125-26-215740.Report this figure133Diluted shares (weighted), Q2 FY2026, three months to 2026-06-30133,480,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure

Shares outstanding: 140.13mShares outstanding, period not labelled, at 2026-07-31140,126,693 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-06, accession 0001193125-26-337952.Report this figure at Jul 31, 2026, from the cover of the 10-Q filed Aug 6, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. Listed shows no prices and gives no investment advice.